Jelena Petkovic Dabic
University Clinical Centre of the Republic of Srpska, Bosnia and Herzegovina
Title: Successful treatment of chronic Hepatitis C infection in Republic of Srpska
Biography
Biography: Jelena Petkovic Dabic
Abstract
Introduction: Viral hepatitis C remains one of the major health and social problems related to infectious diseases. Today, interferon-free therapy using new direct-acting antivirals (DAA) has increased the cure rate across different HCV-infected patient populations. Nowdays, viral hepatitis C threatens to become a healing disease.
Methods: The methodolgy involved a retrospective study. We will present our experiences from the work carried out in 2016 and 2017. We have approved treatment with ombitsvir/paritaprevir/ritonavir + dasabuvir in a total of 55 patients' report.
Results: In 2016, we analyzed 25 patients, 17 (68%) males and 8 (32%) females with age of 26-66 years. In 2017, we analyzed 30 patients, 22 (73%) males and 8 (26,7%) females with age of 23-67 years. Sustained viral response (SVR) is 100%. Adverse events are typically mild, most commonly consisting of fatigue, headache, nausea, and diarrhea.
Discussion/Conclusions: The regimen consisting of ombitasvir/paritaprevir/ritonavir and dasabuvir is highly efficacious in the treatment of viral hepatits C. Today, viral hepatitis C is a curable disease, which reduces membrane damage, as well as the costs of treating patients.